Pro Share Advisors LLC Cerus Corp Transaction History

Pro Share Advisors LLC

  • $48.7 Billion
  • Q2 2025

A detailed history of Pro Share Advisors LLC transactions in Cerus Corp stock. As of the latest transaction made, Pro Share Advisors LLC holds 37,874 shares of CERS stock, worth $59,083. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,874
Previous 39,062 3.04%
Holding current value
$59,083
Previous $54,000 1.85%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 07, 2025
SELL
$1.22 - $1.51 $1,449 - $1,793
-1,188 Reduced 3.04%
37,874 $53,000
Q1 2025

May 08, 2025
SELL
$1.39 - $2.15 $16,339 - $25,273
-11,755 Reduced 23.13%
39,062 $54,000
Q4 2024

Feb 13, 2025
BUY
$1.52 - $2.03 $25,414 - $33,941
16,720 Added 49.04%
50,817 $78,000
Q3 2024

Nov 13, 2024
BUY
$1.7 - $2.39 $17,559 - $24,686
10,329 Added 43.46%
34,097 $59,000
Q2 2024

Aug 13, 2024
SELL
$1.62 - $2.04 $13,144 - $16,552
-8,114 Reduced 25.45%
23,768 $41,000
Q1 2024

May 08, 2024
BUY
$1.66 - $2.42 $4,164 - $6,071
2,509 Added 8.54%
31,882 $60,000
Q4 2023

Feb 14, 2024
BUY
$1.25 - $2.35 $7,898 - $14,849
6,319 Added 27.41%
29,373 $63,000
Q3 2023

Nov 13, 2023
SELL
$1.5 - $3.07 $37 - $76
-25 Reduced 0.11%
23,054 $37,000
Q2 2023

Aug 10, 2023
BUY
$1.79 - $2.9 $4,954 - $8,027
2,768 Added 13.63%
23,079 $56,000
Q1 2023

May 11, 2023
SELL
$2.65 - $3.81 $5,021 - $7,219
-1,895 Reduced 8.53%
20,311 $60,000
Q4 2022

Feb 02, 2023
BUY
$3.38 - $4.22 $10,758 - $13,432
3,183 Added 16.73%
22,206 $81,000
Q3 2022

Nov 04, 2022
SELL
$3.43 - $5.83 $1,251 - $2,127
-365 Reduced 1.88%
19,023 $69,000
Q2 2022

Aug 01, 2022
SELL
$4.41 - $5.69 $53,660 - $69,235
-12,168 Reduced 38.56%
19,388 $103,000
Q1 2022

May 10, 2022
SELL
$4.81 - $6.99 $24,983 - $36,306
-5,194 Reduced 14.13%
31,556 $173,000
Q4 2021

Feb 08, 2022
BUY
$5.97 - $7.93 $90,690 - $120,464
15,191 Added 70.46%
36,750 $249,000
Q3 2021

Nov 12, 2021
SELL
$4.79 - $6.68 $105,763 - $147,494
-22,080 Reduced 50.6%
21,559 $131,000
Q2 2021

Aug 13, 2021
SELL
$5.35 - $6.35 $1,278 - $1,517
-239 Reduced 0.54%
43,639 $258,000
Q1 2021

May 14, 2021
BUY
$5.68 - $7.87 $42,622 - $59,056
7,504 Added 20.63%
43,878 $264,000
Q4 2020

Feb 09, 2021
SELL
$5.25 - $8.56 $55,293 - $90,153
-10,532 Reduced 22.45%
36,374 $252,000
Q3 2020

Nov 13, 2020
SELL
$5.78 - $7.47 $7,618 - $9,845
-1,318 Reduced 2.73%
46,906 $294,000
Q2 2020

Aug 03, 2020
BUY
$4.5 - $7.02 $88,465 - $138,006
19,659 Added 68.82%
48,224 $318,000
Q1 2020

May 15, 2020
SELL
$2.87 - $5.49 $60,835 - $116,371
-21,197 Reduced 42.6%
28,565 $133,000
Q4 2019

Feb 12, 2020
SELL
$3.84 - $4.86 $15,436 - $19,537
-4,020 Reduced 7.47%
49,762 $210,000
Q3 2019

Nov 12, 2019
SELL
$4.86 - $6.05 $3,426 - $4,265
-705 Reduced 1.29%
53,782 $277,000
Q2 2019

Aug 13, 2019
SELL
$4.51 - $6.6 $30,077 - $44,015
-6,669 Reduced 10.9%
54,487 $306,000
Q1 2019

May 15, 2019
BUY
$5.16 - $6.85 $6,088 - $8,083
1,180 Added 1.97%
61,156 $381,000
Q4 2018

Feb 14, 2019
SELL
$4.89 - $7.16 $52,953 - $77,535
-10,829 Reduced 15.29%
59,976 $304,000
Q3 2018

Nov 14, 2018
SELL
$6.89 - $7.78 $7,634 - $8,620
-1,108 Reduced 1.54%
70,805 $511,000
Q2 2018

Aug 13, 2018
SELL
$5.19 - $7.25 $14,070 - $19,654
-2,711 Reduced 3.63%
71,913 $480,000
Q1 2018

May 14, 2018
SELL
$3.56 - $5.74 $12,994 - $20,951
-3,650 Reduced 4.66%
74,624 $409,000
Q4 2017

Feb 14, 2018
BUY
$2.76 - $3.95 $26,805 - $38,362
9,712 Added 14.17%
78,274 $265,000
Q3 2017

Nov 13, 2017
BUY
$2.22 - $2.73 $12,487 - $15,356
5,625 Added 8.94%
68,562 $187,000
Q2 2017

Aug 11, 2017
BUY
N/A
62,937
62,937 $158,000

Others Institutions Holding CERS

# of Institutions
165
Shares Held
139M
Call Options Held
100K
Put Options Held
16K
View Full List

About CERUS CORP

CERS Quotes by TradingView
  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $276M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email